Study S001093

Beijing Chao-Yang Hospital, Capital Medical University

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03297879
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 230
Start: 2013-01-01
Primary completion: 2016-02-28
Lead sponsor: Beijing Chao Yang Hospital
Conditions: Type2 Diabetes
Interventions: DRUG:Exenatide or metformin hydrochloride
Results posted: FALSE

Registered primary outcomes

The change of HbA1c [baseline and 12 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022384	The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes. Zhang L, Frontiers in endocrinology	2022	Other trial	PMID 35432194 DOI	cites ClinicalTrials.gov:NCT03297879; registry reference DERIVED:35432194
R0024694	Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes. Liu J, International journal of endocrinology	2017	Other trial	PMID 29358950 DOI	cites ClinicalTrials.gov:NCT03297879; registry reference DERIVED:29358950